| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Achondroplasia | D000130 | 1 associated lipids |
| Acinetobacter Infections | D000151 | 4 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Acquired Immunodeficiency Syndrome | D000163 | 12 associated lipids |
| Actinomycetales Infections | D000193 | 4 associated lipids |
| Agammaglobulinemia | D000361 | 4 associated lipids |
| Airway Obstruction | D000402 | 13 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lu Y et al. | Antibiotics Promote Escherichia coli-Pseudomonas aeruginosa Conjugation through Inhibiting Quorum Sensing. | 2017 | Antimicrob. Agents Chemother. | pmid:28993333 |
| Bingen E et al. | Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections. | 2003 | Antimicrob. Agents Chemother. | pmid:12821495 |
| Pettus K et al. | In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. | 2015 | Antimicrob. Agents Chemother. | pmid:25624328 |
| Retsema J et al. | Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2449865 |
| Beringer P et al. | Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. | 2005 | Antimicrob. Agents Chemother. | pmid:16304166 |
| Koeva M et al. | An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. | 2017 | Antimicrob. Agents Chemother. | pmid:28923873 |
| Saiz JC and MartÃn-Acebes MA | Reply to Iannetta et al., "Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells". | 2017 | Antimicrob. Agents Chemother. | pmid:28839084 |
| Girard AE et al. | Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. | 1987 | Antimicrob. Agents Chemother. | pmid:2830841 |
| Iannetta M et al. | Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells. | 2017 | Antimicrob. Agents Chemother. | pmid:28839081 |
| Chang HR and Pechère JC | In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. | 1988 | Antimicrob. Agents Chemother. | pmid:2837140 |
| Feola DJ et al. | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. | 2010 | Antimicrob. Agents Chemother. | pmid:20231397 |
| Cynamon MH and Klemens SP | Activity of azithromycin against Mycobacterium avium infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1329622 |
| Seyama S et al. | Amino Acid Substitution in the Major Multidrug Efflux Transporter Protein AcrB Contributes to Low Susceptibility to Azithromycin in Haemophilus influenzae. | 2017 | Antimicrob. Agents Chemother. | pmid:28848006 |
| Wildfeuer A et al. | Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. | 1996 | Antimicrob. Agents Chemother. | pmid:8787883 |
| Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
| Kemp MW et al. | Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. | 2014 | Antimicrob. Agents Chemother. | pmid:25155606 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Zheng S et al. | Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. | 2014 | Antimicrob. Agents Chemother. | pmid:25155592 |
| Engel JN | Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. | 1992 | Antimicrob. Agents Chemother. | pmid:1280057 |
| Saini H et al. | Azithromycin-Ciprofloxacin-Impregnated Urinary Catheters Avert Bacterial Colonization, Biofilm Formation, and Inflammation in a Murine Model of Foreign-Body-Associated Urinary Tract Infections Caused by Pseudomonas aeruginosa. | 2017 | Antimicrob. Agents Chemother. | pmid:28031194 |
| Starner TD et al. | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. | 2008 | Antimicrob. Agents Chemother. | pmid:17954687 |
| Brieland JK et al. | Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10770771 |
| Turcinov D et al. | Failure of azithromycin in treatment of Brill-Zinsser disease. | 2000 | Antimicrob. Agents Chemother. | pmid:10817744 |
| Luke DR et al. | Safety, toleration, and pharmacokinetics of intravenous azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8913468 |
| Tsitsika A et al. | Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis. | 2000 | Antimicrob. Agents Chemother. | pmid:10817749 |
| Olsen KM et al. | Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. | 1996 | Antimicrob. Agents Chemother. | pmid:8913469 |
| Kuo CC et al. | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8913488 |
| Pacifico L et al. | Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. | 1996 | Antimicrob. Agents Chemother. | pmid:8849215 |
| Mukherjee P et al. | Emergence of high-level azithromycin resistance in Campylobacter jejuni isolates from pediatric diarrhea patients in Kolkata, India. | 2014 | Antimicrob. Agents Chemother. | pmid:24777098 |
| Achard A et al. | Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. | 2008 | Antimicrob. Agents Chemother. | pmid:18519724 |
| Zasowski E et al. | Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. | 2014 | Antimicrob. Agents Chemother. | pmid:24752270 |
| Rouse MS et al. | Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. | 1997 | Antimicrob. Agents Chemother. | pmid:9257739 |
| Wong MH et al. | Emergence of clinical Salmonella enterica serovar Typhimurium isolates with concurrent resistance to ciprofloxacin, ceftriaxone, and azithromycin. | 2014 | Antimicrob. Agents Chemother. | pmid:24752251 |
| Jeong BH et al. | Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. | 2016 | Antimicrob. Agents Chemother. | pmid:27480854 |
| Marvig RL et al. | Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. | 2012 | Antimicrob. Agents Chemother. | pmid:22644032 |
| Tomazic J et al. | Ex vivo effect of azithromycin in human leukocyte bactericidal functions. | 1995 | Antimicrob. Agents Chemother. | pmid:7486947 |
| Heifets L et al. | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8031351 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Allen GP and Harris KA | Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. | 2017 | Antimicrob. Agents Chemother. | pmid:28483960 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Caronzolo D et al. | Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15561871 |
| Carter G et al. | A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. | 2004 | Antimicrob. Agents Chemother. | pmid:15561879 |
| Roord JJ et al. | Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. | 1996 | Antimicrob. Agents Chemother. | pmid:9124837 |
| Dreses-Werringloer U et al. | Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. | 2001 | Antimicrob. Agents Chemother. | pmid:11600348 |
| Tateda K et al. | Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. | 2001 | Antimicrob. Agents Chemother. | pmid:11353657 |
| Gödeke J et al. | Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa. | 2013 | Antimicrob. Agents Chemother. | pmid:23318806 |
| Könönen E et al. | beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. | 1999 | Antimicrob. Agents Chemother. | pmid:10223950 |
| Nagaoka K et al. | Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23380724 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
| Akova M et al. | In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. | 1999 | Antimicrob. Agents Chemother. | pmid:10223958 |